CompletedNot Applicable

A REAl-life Study on Short-term DAPT in Patients With Ischemic Stroke or TIA

Italy2,239 participantsStarted 2021-02-03

Plain-language summary

The REAl-life study on short-term Dual Antiplatelet treatment in Patients with ischemic stroke or Transient ischemic attack (READAPT) is an observational, multicenter, prospective study involving Italian centers. The study aims at evaluating effectiveness and safety of short-term (21-90 days) dual antiplatelet treatment (DAPT) in secondary prevention of mild-to-moderate ischemic stroke or high-risk TIA.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria (all to include the patient): * Patients with mild or moderate non-cardioembolic ischemic stroke or high-risk TIA treated with a short course of DAPT (usually 21-30 days but up to 90-day at the physician's discretion) for the acute event; * Male or female aged \>18 years; * Providing signed and dated informed consent; * Willing to comply with all study procedures and to be available for the duration of the study. Exclusion Criteria (one sufficient to exclude the patient): * Patients receiving DAPT after endovascular procedures with stenting; * Patients participating to any interventional RCT on stroke prevention; * Presence of any condition which may preclude reliability of the collected information

What they're measuring

Primary composite outcome

Timeframe: 90 days from DAPT start

Trial details

NCT IDNCT05476081

SponsorUniversity of L'Aquila

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-02-03

View on ClinicalTrials.gov More Ischemic Stroke trials